Product pipeline
Vectura has an innovative and broad clinical pipeline that combines mid- and late-stage programmes with earlier-stage opportunities addressing large and fast-growing market sectors.
The respiratory pipeline comprises inhaled formulations of both branded and generic products for the treatment of asthma, chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF).
Vectura is also exploiting its pulmonary delivery technology for indications such as Parkinson’s disease and migraine, and is exploring additional opportunities for future development.
